A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China

A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China

ClinicalTrials.gov Identifier: NCT04894890

Novartis Reference Number: CAIN457ACN06

Last Update: May 17, 2022

See if you pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation. 

Study Description

This non-interventional, prospective, multi-center study aims to provide short- and long- term treatment patterns, effectiveness, and safety of secukinumab in Chinese patients with moderate to severe plaque psoriasis (with and without PsA) initiating treatment of secukinumab.

Condition 
Psoriasis
Phase 
Not Given
Overall status 
Recruiting
Start date 
Jan 03, 2022
Completion date 
Jun 08, 2023
Gender 
All
Age(s)
18 Years - 100 Years (Adult, Older Adult)

Interventions

Drug
secukinumab
There is no treatment allocation. Patients administered secukinumab by prescription that have started before inclusion of the patient into the study will be enrolled.

Eligibility Criteria

Inclusion Criteria:

Aged ≥ 18 years;
Diagnosis of clinically moderate to severe plaque-psoriasis;
Initiating treatment with secukinumab during the identification period or within 30 days prior to the index date;
Patient agrees to sign the informed consent

Exclusion Criteria:

- Participation in any dermatology or rheumatology clinical trial, concurrent or within the last 30 days of the secukinumab initiating date

Study Locations

China
Novartis Investigative Site
Recruiting
Xicheng Direct, 100044
Beijing
China
Novartis Investigative Site
Recruiting
Chongqing, 400010
Chongqing
China
Novartis Investigative Site
Recruiting
Lanzhou,
Gansu
China
Novartis Investigative Site
Recruiting
Guangzhou, 510000
Guangdong
China
Novartis Investigative Site
Recruiting
Shenzhen, 518020
Guangdong
China
Novartis Investigative Site
Recruiting
Guangdong, 510091
Guangzhou
China
Novartis Investigative Site
Recruiting
Handan, 056002
Hebei
China
Novartis Investigative Site
Recruiting
Zhengzhou, 450003
Henan
China
Novartis Investigative Site
Recruiting
Changsha City, 410011
Hunan
China
Novartis Investigative Site
Recruiting
Changsha, 410003
Hunan
China
Novartis Investigative Site
Recruiting
Suzhou, 215006
Jiangsu
China
Novartis Investigative Site
Recruiting
Yinchuan, 100039
Ningxia
China
Novartis Investigative Site
Recruiting
Jinan, 250021
Shandong
China
Novartis Investigative Site
Recruiting
Jinan, 250022
Shandong
China
Novartis Investigative Site
Recruiting
Shanghai, 200071
Shanghai
China
Novartis Investigative Site
Recruiting
Shanghai, 200072
Shanghai
China
Novartis Investigative Site
Recruiting
Shanghai, 200437
Shanghai
China
Novartis Investigative Site
Recruiting
Chengdu, 610017
Sichuan
China
Novartis Investigative Site
Recruiting
Chengdu, 610041
Sichuan
China
Novartis Investigative Site
Recruiting
Urumqi, 830000
Xinjiang
China
Novartis Investigative Site
Recruiting
Urumqi, 830001
Xinjiang
China
Novartis Investigative Site
Recruiting
Wenzhou, 325000
Zhejiang
China
Novartis Investigative Site
Recruiting
Beijing, 100034
-
China
Novartis Investigative Site
Recruiting
Beijing, 100191
-
China
Novartis Investigative Site
Recruiting
Chongqing, 400011
-
China
Novartis Investigative Site
Recruiting
Jinan, 250012
-
China
Novartis Investigative Site
Recruiting
Tianjin, 300052
-
China
Novartis Investigative Site
Recruiting
Wuhan, 430022
-
China
Novartis Investigative Site
Recruiting
Zhejiang,
-
China

Contacts

Name: 
Novartis Pharmaceuticals
Phone: 

Have a question?

Call 1-888-669-6682 or email [email protected]